PCAS

What PCAS does

SEQENS is a French-headquartered global manufacturer and development partner serving the pharmaceutical, specialty chemical, personal care, and biotechnology sectors. The company operates 15 manufacturing and operational sites across 9 countries, employs approximately 2,700 people, and reports annual revenue of €1 billion. Its commercial portfolio is organized around five product lines: Pharmaceuticals Solutions (generic and custom Active Pharmaceutical Ingredients, intermediates, and excipients), Custom and Specialties (custom specialty ingredients and specialized chemicals), Personal Care ingredients, Cell and Gene therapy manufacturing services delivered through its CELLforCURE subsidiary, and Biotechnologies, including the PeptiCode™ peptide platform. The company serves more than 1,500 customers in over 80 countries and is presented as an integrated development-and-manufacturing partner rather than a pure trader of commodity chemicals.

Underlying technology is built on a global R&D platform comprising 5 research centers staffed by more than 300 scientists, engineers, and specialists. The bench combines organic, inorganic, and physical chemistry with process engineering, polymer science, and physics expertise, supporting development of complex molecules from lab through commercial scale. SEQENS has begun layering biotechnology onto this chemistry base: in April 2026 it launched PeptiCode™ HP-9, positioned as the first European biotech-produced Hexapeptide-9, signaling movement into peptide-based ingredients for personal care and pharmaceutical applications. The CELLforCURE subsidiary provides clinical and commercial-scale cell and gene therapy manufacturing services.

The business model is B2B and transaction-based. SEQENS manufactures and supplies ingredients and intermediates under negotiated, quote-based commercial agreements with pharmaceutical companies, specialty chemical customers, and personal care brands. Pricing is not publicly disclosed. The company has no direct-to-consumer presence and relies on enterprise field sales, content marketing through its Knowledge Center, industry event participation, and LinkedIn for demand generation. Recent activity shows portfolio rationalization alongside innovation: in March 2026 SEQENS sold its Limoges Botanical Actives and In Vitro Diagnostics activities to Solabia, and in April 2026 CELLforCURE initiated a process to find a buyer for its Les Ulis site, while continuing to launch new biotech products such as PeptiCode™ HP-9.

Name

PCAS

Legal name

SEQENS

Website

https://pcas.com

Company type

Private

Founded year

1962

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SEQENS is a French-headquartered global manufacturer and CDMO-style partner producing pharmaceutical APIs and intermediates, specialty chemicals, personal care ingredients, and cell and gene therapy services, operating 15 sites across 9 countries with €1 billion in revenue.

Ownership category

akta.pro rank

Product category

Pharmaceutical Ingredients Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Chemical Manufacturing (325), Pharmaceutical Preparation Manufacturing (325412)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industries

Personal Care & Cosmetic Ingredients (IMAEABAJ), Ingredient Blends & Systems / Custom Formulation (Seasoning Systems, Functional Blends) (CRADAOAO)

Keywords

• Pharmaceutical ingredients manufacturing
• Custom API development
• Specialty chemicals manufacturing
• Personal care ingredients
• Cell and gene therapy manufacturing

Headquarters

HQ city

Longjumeau

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Ingredients and APIs: Manufacturing and sale of generic and custom Active Pharmaceutical Ingredients (APIs), intermediates, and excipients to pharmaceutical companies globally
2. Specialty Chemicals and Custom Ingredients: Development and manufacturing of custom specialty ingredients and specialized chemical products for various industrial applications
3. Personal Care Ingredients: Supply of specialty ingredients for personal care and cosmetic applications
4. Cell and Gene Manufacturing: CELLforCURE operations for cell and gene therapy manufacturing services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

SEQENS manufactures and supplies a broad range of ingredients for the pharmaceutical industry, including generic and custom Active Pharmaceutical Ingredients (APIs), intermediates, and excipients. It also develops custom specialty ingredients, supplies specialty chemicals and personal care ingredients, provides cell and gene therapy manufacturing services through CELLforCURE, and runs biotechnology-based ingredient platforms such as PeptiCode™.

Product overview

SEQENS operates as a global partner in health, personal care and specialty ingredients, offering a unified portfolio of manufacturing and development services. The product portfolio consists of Pharmaceuticals Solutions (Generic and custom APIs, Intermediates, and Excipients), Custom and Specialties (custom specialty ingredients and specialized chemicals), Personal Care ingredients, Cell and Gene therapy manufacturing, and Biotechnologies including the PeptiCode™ peptide platform. The company positions itself as an integrated CDMO (Contract Development and Manufacturing Organization) with R&D capabilities across organic chemistry, inorganic chemistry, process engineering, and biotechnology to serve customers in more than 80 countries.

Differentiator

Problem solved

Functional benefit

Brands

• PeptiCode HP-9: First European biotech Hexapeptide-9 launched April 2026
• CELLforCURE
• NEO Solvents

Products and services

• Pharmaceuticals Solutions Manufactures a broad range of ingredients for the pharmaceutical industry, including generic and custom Active Pharmaceutical Ingredients (APIs), intermediates, and excipients. Serves pharmaceutical companies requiring regulatory-compliant supply and custom molecule development.
• Custom and Specialties Develops custom specialty ingredients and manufactures high-quality specialized chemical products for industrial customers. Targets specialty chemicals buyers needing tailored formulations and complex chemistry support.
• Personal Care Provides specialty ingredient solutions for the personal care industry, supporting formulation and product development needs for cosmetics and personal care brands.
• Cell and Gene (CELLforCURE) Offers cell and gene therapy manufacturing services through the CELLforCURE subsidiary, including clinical and commercial-scale production capabilities for biotech and cell-and-gene therapy developers.
• Biotechnologies Provides biotechnology-based solutions and services, including the PeptiCode™ peptide platform for developing and manufacturing biotech-derived peptide ingredients used in pharmaceutical and personal care applications.
• PeptiCode™ HP-9 Biotech-derived Hexapeptide-9 peptide ingredient produced via the PeptiCode™ platform, marketed as the first European biotech Hexapeptide-9 for use in pharmaceutical and personal care formulations.

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SolabiaminorOthers · 5 March 2026SEQENS sold its Limoges Botanical Actives and In Vitro Diagnostics activities to Solabia in March 2026. This represents a business divestiture rather than a strategic partnership.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Hovione: Portugal-based CDMO specializing in API manufacturing, particle engineering, and inhalation drug delivery. Comparable to SEQENS as a mid-sized European API manufacturer with custom development capabilities.
• Novasep: French CDMO specializing in API manufacturing, purification, and biopharmaceutical services. Directly comparable to SEQENS as a European-based pharma CDMO with overlapping capabilities in custom synthesis and APIs.
• Recipharm: European CDMO focused on sterile fill-finish, APIs, and pharmaceutical development. Directly comparable to SEQENS in pharma CDMO activities, geographic footprint, and customer base across Europe.
• Olon: Italian-headquartered API manufacturer serving generics and CDMO markets globally. Closely comparable to SEQENS' pharmaceutical ingredients and custom API activities with similar European manufacturing footprint.
• Carbogen Amcis: Swiss-based API development and manufacturing company offering drug substance services for complex molecules. Comparable to SEQENS' Custom & Specialties and Pharmaceuticals Solutions businesses in complex molecule development.
• Siegfried Holding: Swiss-headquartered CDMO specializing in APIs, intermediates, and finished dosage forms with global manufacturing sites. Highly comparable to SEQENS in product mix (APIs, intermediates, custom manufacturing) and European base, with similar revenue scale.

Broad incumbents

• Divi's Laboratories: Large Indian-headquartered manufacturer of APIs, intermediates, and custom synthesis services. Comparable to SEQENS in API manufacturing and custom chemistry, though operates at significantly larger scale and from low-cost Asian base.
• Lonza Group: The global leader in pharmaceutical CDMO and API manufacturing with a broad biologics and small molecule portfolio. Comparable to SEQENS as a diversified CDMO serving pharma customers, though Lonza operates at significantly larger scale and broader scope including biologics and mammalian cell culture.
• Catalent: Major global CDMO offering drug substance and drug product development services. Comparable as a pharmaceutical CDMO peer, though Catalent is significantly larger and more focused on biologics/formulation, with broader therapeutic modality coverage.
• Johnson Matthey (Pharmaceutical Materials): Division of Johnson Matthey providing controlled substances, APIs, and catalysts to pharmaceutical companies. Comparable to SEQENS' pharmaceutical ingredients business, though operates as part of a much larger diversified chemicals group.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pcas_2

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PCAS